GlaxoSmithKline ( ($GB:GSK) ) has shared an announcement. GSK has announced that its B7-H3-targeted antibody-drug conjugate, GSK’227, has received ...

In a report released today, Benjamin Jackson CFA from Jefferies upgraded GlaxoSmithKline to a Buy, with a price target of £20.00. The company’s shares opened today at p1,631.50. Take advantage of ...

GlaxoSmithKline (($GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) has announced a new clinical study titled ‘A ...

GSK acquires exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal up to £268 m, reinforcing ...

Part of a pharmaceutical factory which opened more than 75 years ago will be demolished. GSK plc (formerly GlaxoSmithKline) ended its Cumbria operations earlier this year at its Ulverston site, after ...

A pharmaceutical factory which ceased production earlier this year has been bought by Britain's biggest defence firm. BAE ...

SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasisScynexis will promptly wind-down and terminate the MARIO ...

GlaxoSmithKline agreed on Sept. 17 to settle out of the first Zantac trial in California, which began this month in Oakland. GSK won two defense verdicts in Illinois earlier this year but faced 75,000 ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 3.1% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 10.3% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.50. The company’s shares opened today at ...